Skip to main content

Market Overview

House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month

Share:
House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month

The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare. 

The vote was 232 (yes)-193 (no), with 12 Republican members joining their Democratic colleagues to pass the measure.

The Affordable Insulin Now Act would cap insulin prices at either $35 a month or 25% of an insurance plan's negotiated price, whichever is lower. 

The legislation aims to take effect in 2023 regardless of whether a beneficiary has reached the annual out-of-pocket spending threshold and $35 beginning in 2024 for those who have not yet reached this threshold.

"This is a kitchen-table issue: Are people going to be able to pay their bills," House Speaker Nancy Pelosi (D., Calif.) said Thursday. "It paves the way for further action on prescription drugs."

"One in four Americans is forced to skip or ration insulin doses, and that's life-threatening," she said, noting the legislation.

Rep. Cathy McMorris Rodgers (R., Wash.), the top Republican on the Energy and Commerce Committee, said lawmakers should work on alternative legislation that caps insulin costs at $50 a month and requires more transparency from the intermediaries that negotiate pricing with pharmaceutical companies and drugstores, among other steps, writes Wall Street Journal.

Photo by barbhuiya via Unsplash

 

Related Articles (LLY + NVO)

View Comments and Join the Discussion!

Posted-In: DiabetesBiotech Government News Health Care Legal Top Stories General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com